Skip to main content
. Author manuscript; available in PMC: 2022 Jan 18.
Published in final edited form as: Leukemia. 2021 Jul 29;36(1):68–79. doi: 10.1038/s41375-021-01346-7

Figure 3: Igf2bp3 is required for LIC function in endpoint colony formation assays.

Figure 3:

a) Quantification of CD11b+c-Kit+ cells in the spleen of recipient mice at 14 weeks post-transplantation (n=4 Ctrl, n=8 MLL-Af4; one-way ANOVA followed by Bonferroni’s multiple comparisons test; **P < 0.01).

b) Quantitation of CD11b+c-Kit+ cells in the BM 14 weeks post-transplantation (n=4 Ctrl, n=8 MLL-Af4; one-way ANOVA followed by Bonferroni’s multiple comparisons test; **P < 0.01, ***P < 0.001).

c) Expression of IGF2BP3 of in WT/MLL-Af4 and I3KO/MLL-Af4 immortalized Lin- cells at the protein level.

d) Colony formation assay of WT/MLL-Af4 and I3KO/MLL-Af4 immortalized Lin- cells (t-test; **P < 0.01).

e) Schematic of collection of Cas9-GFP MLL-Af4 Lin- cells and CRISPR-Cas9 mediated deletion of Igf2bp3.

f) Expression of Igf2bp3 in Cas9-GFP MLL-Af4 Lin- cells in non-targeting (NT) and Igf2bp3 deleted (I3sg) cells by RT-qPCR.

g) Expression of IGF2BP3 in NT and I3sg Cas9-GFP MLL-Af4 Lin- cells at the protein level.

h) Colony formation assay of NT and I3sg deleted Cas9-GFP MLL-Af4 Lin- cells (t-test; *P < 0.05, **P < 0.01, ***P <0.001).